Dupixent Private Access Program
For Fellows and Trainees
For Health Professionals
Posted 2 months ago
Dupixent (dupilumab) 300 mg injection is now available on prescription for appropriate patients through the Dupixent Private Access Program.
Currently Dupixent is not listed on the Pharmaceutical Benefits Scheme (PBS). This program provides patients with the option to privately fund access to Dupixent while the PBS reimbursement application is ongoing.
Full Product Information is available on the Sanofi-aventis Australia website or by calling 1800 818 806.
For more information about the Private Access Program and how your patients can access Dupixent, please contact the program pharmacist on 1300 021 407 or by email.